Grant of Options

4 July 2013

Omega Diagnostics Group PLC

("Omega" or the "Company")

Grant of Options

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that further to its announcement on 22 April 2013 concerning the appointment of Bill Rhodes as a director of the Company, including an obligation to be granted an option over 2,130,406 ordinary shares of the Company at the prevailing market price at the earliest opportunity, its Remuneration Committee has today confirmed the award of the share options at an exercise price of 15.25p, being the closing mid-market price on 3 July 2013. Following the grant, these options represent Bill Rhodes' only interest in the Company.

The options have been awarded under the Company's Third Unapproved Option Scheme with one third of the options vesting equally over the first, second and third anniversary of the date of grant.

Contacts: